Soligenix, Inc. SNGX 深 沪
等待开盘 03-26 09:30:00 美东时间
1.20
+0.030
+2.56%
华盛通- 最 高1.20
- 今 开1.18
- 成交量 11.01万股
- 最 低 1.16
- 昨 收 1.17
- 总市值 1210.33万
- 52周最高 6.2299
- 市盈率 静 --
- 换手率 1.09%
- 52周最低 1.02
- 委 比 -57.53%
- 总股本 1008.61万
- 历史最高 1219.20
- 量 比 0.86
- 振 幅 3.42%
- 历史最低 1.02
- 每 手 1
- 风险率 0.62%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Soligenix (NASDAQ: SNGX) HyBryte Data To Be Presented At USCLC Workshop Ahead Of AAD Meeting
Austin, Texas, United States, March 24th, 2026, FinanceWire Soligenix(NAS...
03-25 00:30
Soligenix reports HyBryte CTCL clinical trial summary published in Expert Opinion on Investigational Drugs
Soligenix reports HyBryte CTCL clinical trial summary published in Expert Opinion on Investigational Drugs Soligenix reported Phase 3 FLASH trial results showing a 16% response rate with HyBryte versus 4% with placebo at 8 weeks (primary endpoint). In Cycle 2, the response rate was 40% among patient
03-19 19:33
Soligenix reports HyBryte clinical trial summary publication for early-stage CTCL in Expert Opinion on Investigational Drugs
Soligenix reports HyBryte clinical trial summary publication for early-stage CTCL in Expert Opinion on Investigational Drugs Soligenix reported that a clinical summary of trials evaluating HyBryte (synthetic hypericin) for early-stage cutaneous T-cell lymphoma was published in Expert Opinion on Inve
03-19 19:31
Watching Soligenix; Zacks Small-Cap Research Gives Stock $25.00 Price Valuation
https://s27.q4cdn.com/906368049/files/News/2026/Zacks_SCR_Research_03122026_SNGX_Bautz.pdf
03-12 22:06
Soligenix's SGX945 (Dusquetide) Receives Promising Innovative Medicine Designation In U.K. For Behçet's Disease
Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced
03-10 19:35
Soligenix (NASDAQ: SNGX) Leverages Platform Science for Broader Therapeutic Reach
Austin, Texas, United States, March 6th, 2026, FinanceWire Platform-based drug ...
03-06 14:00
Soligenix to Present at BIO Investment & Growth Summit
PRINCETON, N.J., Feb. 24, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing pro...
02-24 20:30
Soligenix Advances Phase 3 FLASH2 Trial for HyBryte in Cutaneous T-Cell Lymphoma
Soligenix Advances Phase 3 FLASH2 Trial for HyBryte in Cutaneous T-Cell Lymphoma Soligenix Inc. has provided an update on its ongoing clinical development of HyBryte™ (SGX301 or synthetic hypericin) for the treatment of early-stage cutaneous T-cell lymphoma (CTCL). The company is conducting the FLAS
02-12 20:34
Soligenix Details Recent Progress and Upcoming Milestones
PRINCETON, N.J., Feb. 12, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing pro...
02-12 20:30
Soligenix Enters $3.45M At-The-Market Equity Sales Agreement With Rodman & Renshaw
Item 8.01.Other Events. On January 23, 2026, Soligenix, Inc. (the "Company") and Rodman & Renshaw, LLC ("Rodman") entered into an At Market Issuance Sales Agreement (as amended, the "Sales Agreement"),
01-24 05:11
